Valdeolivas, Alberto http://orcid.org/0000-0001-5482-9023
Amberg, Bettina http://orcid.org/0000-0002-4526-3897
Giroud, Nicolas
Richardson, Marion
Gálvez, Eric J. C.
Badillo, Solveig
Julien-Laferrière, Alice
Túrós, Demeter
Voith von Voithenberg, Lena
Wells, Isabelle
Pesti, Benedek http://orcid.org/0000-0002-9055-6699
Lo, Amy A.
Yángüez, Emilio http://orcid.org/0000-0003-4271-2690
Das Thakur, Meghna
Bscheider, Michael
Sultan, Marc
Kumpesa, Nadine
Jacobsen, Björn
Bergauer, Tobias
Saez-Rodriguez, Julio http://orcid.org/0000-0002-8552-8976
Rottenberg, Sven http://orcid.org/0000-0003-2044-9844
Schwalie, Petra C.
Hahn, Kerstin http://orcid.org/0000-0003-3602-4234
Funding for this research was provided by:
Roche
Article History
Received: 24 February 2023
Accepted: 4 December 2023
First Online: 10 January 2024
Competing interests
: A.V., B.A., E.G., N.G., M.R., S.B., I.W., B.P., L.V., E.Y., M.B., M.S., N.K., B.J., P.S., T.B. and K.H. are currently employed by F. Hoffmann-La Roche Ltd. A.J.L. and D.T. were previously employed by F. Hoffmann-La Roche Ltd. A.J.L. is currently employed by Idorsia Pharmaceuticals Ltd. D.T. is currently employed by University of Bern. A.L. is currently employed by Genentech, Inc. M.D.T. was previously employed by Genentech, Inc and is currently employed by Gilead Sciences, Inc. J.S.R. has received funding from GSK and Sanofi and fees from Travere Therapeutics and Astex Pharmaceuticals. The authors declare that they have no other competing interests.